To sum up, the present study utilized bioinformatic analysis and in vitro validation to show that PRDM1 increased stomach cancer formation by modulating cell proliferation and BRD4 expression but was counteracted by a BET inhibitor, which provides additional clues to stomach cancer research and treatment. Here, PRDM1 is linked to gastric neoplasm.